Star Equity (NASDAQ:STRR – Get Free Report) and ENDRA Life Sciences (NASDAQ:NDRA – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, institutional ownership and profitability.
Analyst Ratings
This is a summary of recent ratings for Star Equity and ENDRA Life Sciences, as reported by MarketBeat.com.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Star Equity | 0 | 0 | 0 | 0 | N/A |
ENDRA Life Sciences | 0 | 0 | 1 | 0 | 3.00 |
ENDRA Life Sciences has a consensus target price of $9.00, indicating a potential upside of 800.00%. Given ENDRA Life Sciences’ higher probable upside, analysts clearly believe ENDRA Life Sciences is more favorable than Star Equity.
Profitability
This table compares Star Equity and ENDRA Life Sciences’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Star Equity | 32.80% | 7.19% | 3.44% |
ENDRA Life Sciences | N/A | -211.26% | -151.72% |
Volatility and Risk
Star Equity has a beta of 0.23, meaning that its stock price is 77% less volatile than the S&P 500. Comparatively, ENDRA Life Sciences has a beta of 1.04, meaning that its stock price is 4% more volatile than the S&P 500.
Institutional & Insider Ownership
34.4% of Star Equity shares are owned by institutional investors. Comparatively, 6.0% of ENDRA Life Sciences shares are owned by institutional investors. 28.8% of Star Equity shares are owned by insiders. Comparatively, 4.8% of ENDRA Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Earnings & Valuation
This table compares Star Equity and ENDRA Life Sciences’ revenue, earnings per share and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Star Equity | $112.15 million | 0.13 | -$5.25 million | $1.48 | 0.61 |
ENDRA Life Sciences | N/A | N/A | -$13.18 million | ($2.80) | -0.36 |
Star Equity has higher revenue and earnings than ENDRA Life Sciences. ENDRA Life Sciences is trading at a lower price-to-earnings ratio than Star Equity, indicating that it is currently the more affordable of the two stocks.
Summary
Star Equity beats ENDRA Life Sciences on 9 of the 12 factors compared between the two stocks.
About Star Equity
Star Equity Holdings, Inc. provides healthcare solutions in the United States and internationally. It operates through four segments: Diagnostic Services, Diagnostic Imaging, Construction, and Investments. It offers imaging services primarily to cardiologists, internal medicine physicians, and family practice doctors; and imaging systems, including nuclear cardiac and general purpose nuclear imaging systems to physician offices and hospitals. The company also develops, sells, and maintains solid-state gamma cameras; and provides camera maintenance contract services. In addition, it manufactures modular housing units, structural wall panels, permanent wood foundation systems, and other engineered wood products; supplies general contractors with building materials; holds real estate assets; and manages investments. The company was formerly known as Digirad Corporation and changed its name to Star Equity Holdings, Inc. in December 2020. Star Equity Holdings, Inc. was founded in 1985 and is headquartered in Old Greenwich, Connecticut.
About ENDRA Life Sciences
ENDRA Life Sciences Inc. develops technology for improving the capabilities of clinical diagnostic ultrasound. The company develops thermo-acoustic enhanced ultrasound technology that transmits sound waves, which bounce off tissues, organs, and blood in the body for use in the treatment of nonalcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion. It also offers diagnostic imaging technologies, such as computed tomography, magnetic resonance imaging, and ultrasound that allow physicians to look inside a person’s body to guide treatment or gather information about medical conditions, such as broken bones, cancers, signs of heart disease, or internal bleeding. The company has a collaborative research agreement with General Electric Company. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.
Receive News & Ratings for Star Equity Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Star Equity and related companies with MarketBeat.com’s FREE daily email newsletter.